Indication-specific documentation

Document the known or suspected disorder and the clinical indications that align with this policy to support performing nerve conduction studies (NCS) with or without needle electromyography (EMG) or NCS alone when allowed (e.g., anticoagulation status, lymphedema, evaluation for carpal tunnel syndrome, peripheral neuropathy, plexopathy, neuromuscular junction disorders, myopathy, motor neuron disease, radiculopathy, or need for treatment guidance such as muscle localization for botulinum toxin).

Performance and supervision requirements

Needle EMG must be performed by a physician specially trained in electrodiagnostic (EDX) medicine. NCS may be performed by a trained physician or a trained technician but must be under the direct supervision of a physician; the EDX physician should supervise data collection, be immediately available as required, and integrate history, tailored testing, and waveform analysis in real time when appropriate. Data collection may be delegated to trained technologists or qualifying trainees, but the EDX physician retains supervision and review responsibilities.

State fee schedule notice

The following HCPCS/CPT codes are referenced in the policy and may not be on the New Jersey Medicaid fee schedule: 0106T, 0107T, 0108T, 0109T, 0110T, 0464T, 0778T, A9279, A9280, G0255, S3900. Verify coverage and reimbursement with the NJ Medicaid fee schedule prior to billing, as codes marked with an asterisk in the policy are not on the State of New Jersey Medicaid Fee Schedule and therefore may not be covered.

• 0106T
• 0107T
• 0108T
• 0109T
• 0110T
• 0464T
• 0778T
• A9279
• A9280
• G0255
• S3900

Rationale for wearable seizure detector use

When using wearable seizure detection devices for generalized tonic-clonic seizures (GTCS) or focal to bilateral tonic-clonic seizures (FBTCS), document that significant safety concerns exist and that alarms will enable rapid, alarm‑triggered intervention — ideally within about 5 minutes — consistent with guideline rationale for use of clinically validated devices in these seizure types.

Consideration for coverage authorization

Prior authorization may be required for coverage of wearable seizure detection devices. When seeking authorization, document the clinical indication for monitoring, a clear safety rationale (e.g., risk of injury or unattended seizures), and a plan for alarm response including ability to intervene rapidly after an alarm (ideally within 5 minutes) to align with guideline recommendations.

QST testing limitations

Document that quantitative sensory testing (QST) is being used only as an adjunct to the clinical examination and electrodiagnostic testing and not as the sole diagnostic method, due to reproducibility, standardization, and evidence limitations.

Device placement and monitoring specifics

If coverage is approved for a device-based monitoring approach, ensure that device placement and monitoring procedures match the validated study methods used in evidence supporting the device (performance varied substantially by placement and algorithm); for example, sEMG seizure detection performance improved with midline biceps placement in trials.

Reference federal/state/contractual plan terms

Reference and follow any applicable federal, state, or contractual benefit requirements when deciding coverage and documenting justification, since those requirements may differ from this policy and will govern in the event of conflict.

CPT code list updates

Do not bill CPT code 96003. This CPT code was removed from the applicable CPT code list effective 04/01/2025 per the policy revision; update billing practices to reflect the annual CPT edits.

• 96003

Use of Third-Party Criteria

UnitedHealthcare may use InterQual or other third‑party tools to assist in administering benefits; note this potential use when documenting justification for coverage decisions.